Rodriguez CA, Beard A, Symonds WT, Hill G and Berrey MM (Pharmasset,
Christchurch Clinical Studies Trust and Roche Palo Alto).
-- Abstract P-262: The Mechanism of Action of Beta-D-2'-Deoxy-2'-fluoro-
2'-C-methylcytidine Involves a Second Metabolic Pathway Leading to
Beta-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine 5'-Triphosphate, a Potent
Inhibitor of the HCV RNA-Dependent RNA Polymerase. Murakami E, Niu C,
Bao H, Micolochick Steuer HM, Otto MJ and Furman PA (Pharmasset).
-- Abstract P-265: The Nucleoside Inhibitors R1479, PSI-6130, and NM107
have a Higher Genetic Barrier to Resistance than the Non-nucleoside
Inhibitor HCV-796 and the Protease Inhibitor VX-950. McCown M,
Rajyaguru S, Symons J, Cammack N and Najera I (Roche Palo Alto).
-- Abstract P-263: In Vitro Selection and Characterization of HCV
Replicons Resistant to PSI-6130. Ali S, Leveque V, LePogam S, Ma H,
Philipp F, Najera I, Klumpp K, Symons J, Cammack N and Jiang WR (Roche
-- Abstract P-259: Beta-D-2'-Deoxy-2'-fluoro-2'-C-methyluridine
Phosphoramidates: Potent and Selective Inhibitors of HCV RNA
Replication. Sofia MJ, Wang P, Du J, Micolochick Steuer HM, Niu C,
Furman PA and Otto MJ (Pharmasset).
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Pharmasset is currently developing three product candidates. Clevudine,
for the treatment of chronic HBV infection, is expected to enter Phase 3
clinical trials for registration in the Americas and Europe. Clevudine is
already approved for HBV in South Korea and marketed by
|SOURCE Pharmasset, Inc.|
Copyright©2007 PR Newswire.
All rights reserved